Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case-control study.

摘要

Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor antagonists (ARAs) are among the most prescribed antihypertensive agents used by physicians around the world. Furthermore, following the publication of various renin-angiotensin-aldosterone system blockade trials in the last two decades including the Collaborative Study Group in 1993, the ELITE II study in 2000, the IDNT and RENAAL studies in 2001, and the CHARM studies in 2003, the US Food and Drug Administration's approved list of indications for ACE-Is and ARAs has grown to include hypertension, renoprotection in both diabetic and nondiabetic chronic kidney disease (CKD), following acute myocardial infarction, and for systolic heart failure. As far back as 2000, nearly 80% of some US diabetic patients were receiving an ACE-I, an ARA, or a combination of both agents.